Patient and graft characteristics
Pretransplantation characteristics . | Data . |
|---|---|
| No. pts | 34 |
| Age, y, median (range) | 63 (60-74) |
| Disease, no. pts (%) | |
| De novo AML | 15 (44) |
| s/tAML | 13 (38) |
| MDS | 6 (18) |
| Disease risk, no. pts (%)* | |
| High | 30 (88) |
| Intermediate | 4 (12) |
| Disease status at HCT, no. pts (%) | |
| CR-1 | 1 (3) |
| CR-2 | 2 (6) |
| Untreated | 11 (32) |
| Induction failure | 11 (32) |
| REL-1 untreated | 7 (21) |
| REL-1 refractory | 2 (6) |
| Graft, no. pts (%) | |
| PB-HCT | 30 (88) |
| BMT | 4 (12) |
| BM blasts at HCT, %, median (range) | 30 (0-98) |
| PB blasts at HCT, no. pts (%) | 22 (65) |
| Neutropenic at HCT, no. pts (%) | 15 (44) |
| No. prior therapies, median (range) | 2 (0-7) |
| Aspergillosis/sepsis, no. pts (%)† | 7 (21) |
| KPS at HCT, %, median (range) | 80 (40-100) |
Pretransplantation characteristics . | Data . |
|---|---|
| No. pts | 34 |
| Age, y, median (range) | 63 (60-74) |
| Disease, no. pts (%) | |
| De novo AML | 15 (44) |
| s/tAML | 13 (38) |
| MDS | 6 (18) |
| Disease risk, no. pts (%)* | |
| High | 30 (88) |
| Intermediate | 4 (12) |
| Disease status at HCT, no. pts (%) | |
| CR-1 | 1 (3) |
| CR-2 | 2 (6) |
| Untreated | 11 (32) |
| Induction failure | 11 (32) |
| REL-1 untreated | 7 (21) |
| REL-1 refractory | 2 (6) |
| Graft, no. pts (%) | |
| PB-HCT | 30 (88) |
| BMT | 4 (12) |
| BM blasts at HCT, %, median (range) | 30 (0-98) |
| PB blasts at HCT, no. pts (%) | 22 (65) |
| Neutropenic at HCT, no. pts (%) | 15 (44) |
| No. prior therapies, median (range) | 2 (0-7) |
| Aspergillosis/sepsis, no. pts (%)† | 7 (21) |
| KPS at HCT, %, median (range) | 80 (40-100) |
All patients received the FBM preparative regimen and allografted from unrelated donors. All except one patient received ATG.
pts indicates patients; s/tAML, acute myelogenous leukemia (secondary/therapy related); MDS, myelodysplastic syndrome; HCT, hematopoietic cell transplantation; CR, complete remission; REL, relapse; PB-HCT, HCT with cytokine-mobilized peripheral blood (PB) cells; BMT, bone marrow (BM) transplantation; KPS: Karnofsky performance score; d +, day after transplantation; CC, complete chimerism; OS, overall survival; EFS, event-free survival; and NRM, nonrelapse mortality.
Classification according to response to remission induction chemotherapy and cytogenetics
History of aspergillosis or severe sepsis